The Champalimaud Foundation has installed Lonza’s Moda-Es manufacturing execution system
Biomedical research organisation Champalimaud Foundation has installed manufacturer Lonza’s Moda-Es Platform at its Lisbon clinical centre.
Lonza’s Moda-Es manufacturing execution system is designed specifically for cell and gene therapy production. It consolidates all manufacturing batch and batch-related quality control data into a single record for reduced errors, greater visibility and expedited product release.
“We are committed to supporting our customers in bringing innovative cell and gene therapies to their patients,” said Orla Cloak, the senior vice president and head of bioscience at Lonza.
“This commitment relies on our capability to offer the right expertise and tools, including Moda-Es. We are also proud to support our customers with an experienced implementation team that understands the intricacies of cell and gene therapy manufacture and can help to accelerate the path to market for these novel therapies.”
Lonza’s Moda-Es platform’s advanced traceability and genealogy workflows help to ensure the chain of identity and custody in complex, decentralised cell and gene therapy manufacturing processes.
The platform also accommodates Champalimaud Foundation’s desire for a paperless solution and electronic record-keeping to ensure the safety of cell production, unlock transparency for partners and monitor the complex production process.
Aiming to improve and streamline cell therapy manufacturing, the foundation’s multipurpose GMP facility will develop promising cell therapies with industrial standards.
The plan is to increase the accessibility of life-saving therapies for patients.
